Lipid Disorders
From the Journals
Early treatment may delay atherosclerosis in familial hypercholesterolemia
Cholesterol-lowering treatment early in life appeared to slow intima-media growth in a meta-analysis.
From the Journals
Irregular and long periods linked to NAFLD
When compared with regular menstrual cycles, irregular cycles were associated with nonalcoholic fatty liver disease in a study, but experts are...
From the Journals
How Lp(a) can help improve ASCVD risk assessment
Calcium scores and lipoprotein(a) levels predict 10-year risk independent of each other, and together could swing shared decision-making about...
From the Journals
Autoantibodies may underpin clotting effects of COVID-19
Researchers discovered “rogue” antibodies associated with clotting and inflammation in severe COVID-19.
From the Journals
More than half of U.S. women enter pregnancy at higher CVD risk
A minority of women in the United States enter pregnancy in favorable cardiovascular health, new research suggests.
From the Journals
AHA targets ‘low-value’ heart care in new scientific statement
Low-value cardiovascular care providing little or no benefit is common, potentially harmful, and costly, and it will take key stakeholders to...
Latest News
USPSTF tweaks primary prevention statin recommendations in new draft guidance
The task force concluded “with moderate certainty” that a statin prescription will clinically benefit adults 40-75 years without CVD but with at...
From the Journals
Full-press therapy rare in diabetes with ASCVD
From the Journals
Statin intolerance ‘overestimated and overdiagnosed’
Fewer than 10% of patients experience statin intolerance, meaning that the vast majority of patients can be treated effectively, with very good...
From the Journals
Study questions need for repeat Lp(a) testing
A large cohort study finds that a baseline test for lipoprotein(a) can help determine cardiovascular disease risk and that repeat testing isn't...
Feature
Novel drug targets raised Lp(a): topline results released
Significant reductions in lipoprotein(a) were sustained out to 150 days in patients without cardiovascular disease in top-line phase 1 results...